<DOC>
	<DOC>NCT02020876</DOC>
	<brief_summary>This clinical utility study pilot is based on a review of real but de-identified and randomized patient cases and aims to evaluate Urologists' treatment recommendations before and after reviewing the results provided by the Decipher test. This is a pilot study and the primary intent is to help guide development and design of future clinical utility studies for Decipher</brief_summary>
	<brief_title>Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations</brief_title>
	<detailed_description>The primary and secondary objectives will be assessed in retrospectively selected prostate cancer patients treated with radical prostatectomy with one or more adverse pathological features (APFs)</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Criteria (Participant enrollment) Inclusion Criteria Study participants: 1. Practicing boardcertified urologic surgeons 2. Performing at least 40 radical prostate surgeries annually Exclusion Criteria Study Participants: (1) Did not meet the inclusion criteria Criteria (Case selection) Inclusion Criteria Case File: Patient cases eligible for this study were treated with radical prostatectomy and have one or more adverse pathological features present defined as: Pathological Gleason score &gt;= 8 or Gleason score 7 with primary pattern 4; Pathological stage T3A (= Extraprostatic extension) or T3B (=Seminal vesicle invasion); Positive surgical margins Gleason grade upgrade from biopsy to surgery Exclusion Criteria Case File: Metastatic disease (M+) prior to surgery Received any neoadjuvant prostate cancer treatment with radical prostatectomy (radiation, hormone, chemotherapy)</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>